Intercept’s NASH Hopes: A Case Study For Implications Of US Pricing Bill
Interecept is reviving hopes that it will be able to capture a potential blockbuster indication for its liver disease drug Ocaliva. The development strategy might never happen again if the US drug pricing bill becomes law.
You may also be interested in...
‘It takes longer than nine years’ to profit from small molecule drug R&D, company CEO maintains in arguments against the negotiation process, and its timelines, in the Senate drug pricing reform legislation.
US Senate’s updated version of drug pricing legislation is even worse for industry when it comes to the proposed price ‘negotiation’ authority, a Congressional Budget Office analysis indicates. The big numbers facing the industry just keep getting bigger.
The final push by Democrats to enact a drug price ‘negotiation’ bill is under way. The prospects are uncertain, but the intended impact is not: never again will there be a brand as successful for as long as Humira.